Education
About Us
Working with TipRanks
Follow Us
Rocket Pharmaceuticals (DE:9IP1)
FRANKFURT:9IP1
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ -11.03M | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Operating Income | $ -228.52M | $ -273.20M | $ -259.66M | $ -224.34M | $ -167.25M |
| EBITDA | $ -210.21M | $ -247.49M | $ -236.62M | $ -213.69M | $ -157.81M |
| Net Income | $ -223.12M | $ -258.75M | $ -245.59M | $ -221.86M | $ -169.07M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 77.56M | $ 372.34M | $ 373.18M | $ 356.39M | $ 388.74M |
| Total Assets | $ 330.45M | $ 527.70M | $ 566.34M | $ 551.81M | $ 497.02M |
| Total Debt | $ 24.88M | $ 25.50M | $ 25.04M | $ 22.87M | $ 22.60M |
| Net Debt | $ -52.68M | $ -138.14M | $ -30.86M | $ -117.65M | $ -210.09M |
| Total Liabilities | $ 53.23M | $ 64.47M | $ 73.77M | $ 62.12M | $ 42.30M |
| Stockholders' Equity | $ 277.22M | $ 463.23M | $ 492.57M | $ 489.69M | $ 454.72M |
| Cash Flow | |||||
| Free Cash Flow | $ -190.45M | $ -215.59M | $ -211.39M | $ -186.76M | $ -128.88M |
| Operating Cash Flow | $ -190.01M | $ -209.72M | $ -194.92M | $ -178.14M | $ -121.16M |
| Investing Cash Flow | $ 103.77M | $ 131.71M | $ -98.07M | $ -69.33M | $ 18.85M |
| Financing Cash Flow | $ 148.00K | $ 185.74M | $ 208.40M | $ 155.29M | $ 37.68M |